India Trials Show DCT Adds Year To Life Of Refractory Cancer Patients
This article was originally published in PharmAsia News
Executive Summary
Phase II clinical trials at six sites in India show dendritic cell therapy, now a fourth-line treatment for refractory cancer patients expected to live no more than three months, extended their survival rate by about a year.